Literature DB >> 1262447

Nocturnal elevation of plasma melatonin and urinary 5-hydroxyindoleacetic acid in young men: attempts at modification by brief changes in environmental lighting and sleep and by autonomic drugs.

G M Vaughan, R W Pelham, S F Pang, L L Loughlin, K M Wilson, K L Sandock, M K Vaughan, S H Koslow, R J Reiter.   

Abstract

In order to determine whether the human pattern of circulating melatonin resembles that previously described in lower animals, men 19-32 years old were exposed to a light-dark cycle with 14 hours of light per day (L:D 14:10). In whites and blacks, nocturnal (dark phase, sleeping) melatonin levels were almost always elevated to 0.05-0.1 ng/ml plasma compared with lower or undetectable levels during the day, measured by the tadpole bioassay. Thin-layer migration of bioactive material was identical to that for melatonin standard. A rhythm with nocturnal elevation of urinary 5-hydroxyindoleacetic acid (5-HIAA) was observed. Nocturnal (sleep phase) rise in blood melatonin (but not urinary 5-HIAA) continued during 21/2 day-night cycle lengths after the onset of constant light. Though the dark phase plasma melatonin rise was less marked after reversal of the sleep-wake cycle (no change in the light cycle), dark phase rise in urinary 5-HIAA continued. Though marked cardiovascular and other effects were produced by intravenous isoproterenol or scopolamine, no definite effect on melatonin levels was observed after either drug during the light phase in waking subjects.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1262447     DOI: 10.1210/jcem-42-4-752

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

Review 1.  Utilizing melatonin to combat bacterial infections and septic injury.

Authors:  Wei Hu; Chao Deng; Zhiqiang Ma; Dongjin Wang; Chongxi Fan; Tian Li; Shouyin Di; Bing Gong; Russel J Reiter; Yang Yang
Journal:  Br J Pharmacol       Date:  2017-03-21       Impact factor: 8.739

2.  Circadian variation in urinary melatonin in clinically healthy women in Japan and the United States of America.

Authors:  L Wetterberg; F Halberg; B Tarquini; M Cagnoni; E Haus; K Griffith; T Kawasaki; L A Wallach; M Ueno; K Uezo; M Matsuoka; M Kuzel; E Halberg; T Omae
Journal:  Experientia       Date:  1979-03-15

3.  Postsynaptic alpha-adrenergic receptors potentiate the beta-adrenergic stimulation of pineal serotonin N-acetyltransferase.

Authors:  D C Klein; D Sugden; J L Weller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

4.  Atenolol reduces plasma melatonin concentration in man.

Authors:  P J Cowen; S Fraser; R Sammons; A R Green
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

5.  Pigment aggregation by melatonin in the retinal pigment epithelium and choroid of guinea-pigs, Caviaporcellus.

Authors:  S F Pang; D T Yew
Journal:  Experientia       Date:  1979-02-15

6.  Suicidal ideation and biogenic amines in depression.

Authors:  V Palaniappan; V Ramachandran; O Somasundaram
Journal:  Indian J Psychiatry       Date:  1983-10       Impact factor: 1.759

7.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

8.  The human pineal gland responds to stress-induced sympathetic activation in the second half of the dark phase: preliminary evidence.

Authors:  P Monteleone; M Maj; F Franza; R Fusco; D Kemali
Journal:  J Neural Transm Gen Sect       Date:  1993

9.  Influence of chronic beta-adrenoreceptor blocker treatment on melatonin secretion and sleep quality in patients with essential hypertension.

Authors:  T Rommel; L Demisch
Journal:  J Neural Transm Gen Sect       Date:  1994

Review 10.  Response of pineal serotonin N-acetyltransferase activity in male guinea pigs exposed to light pulses at night.

Authors:  L Vollrath; A Huesgen
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.